Novartis Galvus India Case: Wockhardt Pulls Back?
Executive Summary
Legal proceedings around Novartis' Galvus patent in India appear to have taken an interesting turn, with generic challenger Wockhardt indicating that it will retract its application for the revocation of the patent on the diabetes drug.
You may also be interested in...
Final Salvo? Galvus Infringement Case Simmers In India
Natco has sprung a challenge to Novartis’ vildagliptin patent in India, months before its expiry. The Indian firm will hold back further release of its product on the market amid legal action and it remains to be seen if Novartis will pursue damages.
Novartis Diabetes Triple Drug Combination Deemed 'Irrational' In India
Novartis’s plans for triple drug diabetes combination which includes vildagliptin have been turned down in India at least for now, with an expert panel questioning the rationale of such therapy.
Pricing Tensions Escalate In India; Novartis Under A Cloud
Charges of price collusion pertaining to Novartis’ Galvus are the latest in a string of allegations that have rocked the pharmaceutical industry in India over the recent past, though the company claims it has not flouted the law. Industry is also under fire for ‘suspected’ deviations from mandated price caps for over 600 medicines – a charge seen widening the trust deficit.